- Home
- TGTX vs BCC Comparison
TGTX vs BCC Comparison
Compare TGTX & BCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- BCC
- Stock Information
- Founded
- TGTX 1993
- BCC 2004
- Country
- TGTX United States
- BCC United States
- Employees
- TGTX N/A
- BCC N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- BCC RETAIL: Building Materials
- Sector
- TGTX Health Care
- BCC Consumer Discretionary
- Exchange
- TGTX Nasdaq
- BCC Nasdaq
- Market Cap
- TGTX 5.4B
- BCC 5.3B
- IPO Year
- TGTX 1995
- BCC 2013
- Fundamental
- Price
- TGTX $32.91
- BCC $132.56
- Analyst Decision
- TGTX Strong Buy
- BCC Buy
- Analyst Count
- TGTX 6
- BCC 5
- Target Price
- TGTX $40.67
- BCC $139.60
- AVG Volume (30 Days)
- TGTX 2.3M
- BCC 209.9K
- Earning Date
- TGTX 11-04-2024
- BCC 11-04-2024
- Dividend Yield
- TGTX N/A
- BCC 4.34%
- EPS Growth
- TGTX N/A
- BCC N/A
- EPS
- TGTX N/A
- BCC 10.21
- Revenue
- TGTX $264,790,000.00
- BCC $6,801,070,000.00
- Revenue This Year
- TGTX $43.74
- BCC N/A
- Revenue Next Year
- TGTX $64.30
- BCC $5.05
- P/E Ratio
- TGTX N/A
- BCC $13.13
- Revenue Growth
- TGTX 39.53
- BCC N/A
- 52 Week Low
- TGTX $12.84
- BCC $113.89
- 52 Week High
- TGTX $36.84
- BCC $155.42
- Technical
- Relative Strength Index (RSI)
- TGTX 55.20
- BCC 38.09
- Support Level
- TGTX $30.41
- BCC $133.00
- Resistance Level
- TGTX $35.03
- BCC $147.47
- Average True Range (ATR)
- TGTX 1.55
- BCC 3.29
- MACD
- TGTX -0.33
- BCC -1.57
- Stochastic Oscillator
- TGTX 51.78
- BCC 9.83
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
About BCC Boise Cascade L.L.C.
Boise Cascade Co is a producer of engineered wood products (EWP) and plywood. The firm operates in two segments namely Wood Products and Building Materials Distribution. Wood Products segment manufactures EWP, consisting of laminated veneer lumber (LVL), I-joists, and laminated beams. The Building Materials Distribution segment is engaged in the wholesale of building materials. It distributes products such as plywood, OSB, and lumber items such as siding, doors, metal products, insulation, and roofing, EWP and others. The company generates a majority of its revenue from the Building Material Distribution segment.